Gilead Sciences Inc plans to make more of its drug remdesivir available for Germany and Europe from autumn and will decide how much each country gets based on the rate of infection, the drugmaker’s Germany boss told a German magazine. Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December. …read more
Source:: Yahoo Finance
